Get the Stockscreener App
3.77
4.31%
-0.17
After Hours:
3.80
0.03
+0.80%
Camp 4 Therapeutics Corp stock is traded at $3.77, with a volume of 70,472.
It is down -4.31% in the last 24 hours and up +24.42% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$3.94
Open:
$3.92
24h Volume:
70,472
Relative Volume:
0.09
Market Cap:
$76.01M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-0.9204
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
-3.58%
1M Performance:
+24.42%
6M Performance:
+93.33%
1Y Performance:
-54.14%
1-Day Range:
$3.62
$4.1399
1-Week Range:
$3.51
$4.24
52-Week Range:
$1.305
$12.26
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.77 | 79.43M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Chart based exit strategy for Camp4 Therapeutics Corporation2025 Price Momentum & Consistent Income Trade Ideas - newser.com
Real time breakdown of Camp4 Therapeutics Corporation stock performanceJuly 2025 Decliners & Capital Efficient Trade Techniques - newser.com
Does Camp4 Therapeutics Corporation qualify in momentum factor screeningQuarterly Profit Review & Long Hold Capital Preservation Plans - newser.com
How Camp4 Therapeutics Corporation stock trades before earningsMarket Movement Recap & Long-Term Investment Growth Plans - newser.com
Risk adjusted return profile for Camp4 Therapeutics Corporation analyzedJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Can Camp4 Therapeutics Corporation stock sustain revenue growth2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
How Camp4 Therapeutics Corporation stock reacts to global recession fearsLayoff News & Smart Swing Trading Techniques - newser.com
Can Camp4 Therapeutics Corporation stock weather global recessionGap Up & Safe Swing Trade Setups - newser.com
How moving averages guide Camp4 Therapeutics Corporation trading2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Can Camp4 Therapeutics Corporation stock reach $100 price targetCEO Change & Low Risk High Win Rate Picks - newser.com
What to do if you’re stuck in Camp4 Therapeutics CorporationWeekly Gains Summary & Smart Money Movement Alerts - newser.com
How to interpret RSI for Camp4 Therapeutics Corporation stockJuly 2025 Rallies & High Yield Stock Recommendations - newser.com
Volume spikes in Camp4 Therapeutics Corporation stock – what they meanStop Loss & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-10-19 02:06:54 - nchmf.gov.vn
Is Camp4 Therapeutics Corporation stock a safe buy before earningsJuly 2025 Recap & Weekly Momentum Picks - Trung tâm Dự báo KTTV quốc gia
Can Camp4 Therapeutics Corporation stock sustain market leadershipInflation Watch & Stock Portfolio Risk Control - nchmf.gov.vn
Combining price and volume data for Camp4 Therapeutics CorporationJuly 2025 Update & Real-Time Chart Pattern Alerts - newser.com
CAMP4 Therapeutics CorporationCommon Stock (NQ: - FinancialContent
3 Healthcare Companies Insiders Are Buying - The Globe and Mail
Is Camp4 Therapeutics Corporation a good long term investmentCup and Handle Formations & Low Entry Investment Portfolio - earlytimes.in
CAMP Form 3: Dr. Tardiff Discloses 74,578 Stock Options - Stock Titan
Will Camp4 Therapeutics Corporation continue its uptrendPortfolio Return Report & AI Powered Market Entry Ideas - newser.com
CAMP4 Therapeutics stock soars after $100 million private placement By Investing.com - Investing.com Nigeria
[SCHEDULE 13G] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Aims For The Summit: Unlocking The Therapeutic Power Of RegRNA, Once Deemed Undruggable - RTTNews
Camp4 Therapeutics Corporation Stock Analysis and ForecastSector Performance Review & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Cantor Fitzgerald initiates CAMP4 Therapeutics stock with Overweight rating - Investing.com
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy By Investing.com - Investing.com Nigeria
Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01 - MarketScreener
CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - TipRanks
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy - Investing.com India
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - GlobeNewswire
Potential Breakthrough for Rare Brain Disorder: CAMP4's SYNGAP1 Drug Enters Final Pre-Clinical Stage - Stock Titan
What analysts say about Camp4 Therapeutics Corporation stockReal Estate Investment Trusts & These 3 Stocks Could Change Your Portfolio - Early Times
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):